Dr. Salvi graduated in Medicine and trained in Endocrinology in Parma, Italy. He carried out post-doc research projects at McGill University in 1985-91 with specific focus on the pathogenesis of Graves' disease and orbitopathy. He continued his work in Parma until 2001 and from 2002 at the University of Milan. He is heading a Graves' Orbitopathy Center of the Fondazione IRCCS Cà Granda, Milan. Since 2003 he has pioneered immunotherapy and has been carrying out clinical studies with rituximab, the anti-BAFF belimumab, the anti-IGF-1 receptor antibody teprotumumab, and the anti-Il-6 receptor antibody tocilizumab in Graves' orbitopathy, in addition to multicenter trials carried out within EUGOGO. He has contributed to the book: "Graves' Orbitopathy: a multidisciplinary approach" edited by EUGOGO, and has co-authored the ATA/ETA consensus document on Graves' orbitopathy. He has published more than 190 papers (H-Index 45) and gave more than 200 scientific communications and invited lectures at international meetings.